Country: Awstralja
Lingwa: Ingliż
Sors: Department of Health (Therapeutic Goods Administration)
neostigmine methylsulfate, Quantity: 2.5 mg
Juno Pharmaceuticals Pty Ltd
neostigmine methylsulfate
Injection, solution
Excipient Ingredients: water for injections; sodium chloride
Intramuscular, Intravenous, Subcutaneous
10 ampoules, 50 ampoules
(S4) Prescription Only Medicine
Neostigmine is indicated for:,? Reversal of the effects of non-depolarising neuromuscular blocking agents.,? Prophylaxis and treatment of post-operative intestinal atony and urinary retention.,? Treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.
Visual Identification: Clear, colourless solution; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-01-27
_Neostigmine Juno Solution for Injection – Consumer Medicine Information _ _ _ _15.JU.M.1.0 _ _ _ _ _ _Page 1 _ NEOSTIGMINE JUNO SOLUTION FOR INJECTION _Neostigmine Methylsulfate_ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about Neostigmine Juno Solution for Injection. It does not contain all the information that is known about Neostigmine Juno Solution for Injection. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor will have weighed the risks of you being given Neostigmine Juno Solution for Injection against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE TALK TO YOUR DOCTOR OR PHARMACIST. Keep this leaflet. You may need to read it again. WHAT NEOSTIGMINE JUNO IS USED FOR Neostigmine Juno Solution for Injection increases movement of the muscles in the body. It can be used: • To reverse the effects of medicines that are used to stop muscles moving; • To activate the muscles in the bladder, stomach and intestines following surgery • For myasthenia gravis. Neostigmine is known as a cholinesterase inhibitor. It works by stopping a chemical called acetylcholine, which stimulates muscles movement, from breaking down. Your doctor will have explained why you are being treated with Neostigmine Juno Solution for Injection. FOLLOW ALL DIRECTIONS GIVEN TO YOU BY YOUR DOCTOR CAREFULLY. They may differ from the information contained in this leaflet. Your doctor may prescribe this medicine for another use. Ask your doctor if you want more information. Neostigmine Juno Solution for Injection is not addictive. BEFORE YOU ARE GIVEN NEOSTIGMINE JUNO You may already have been given Neostigmine Juno Solution for Injection. Your doctor will have considered the situation carefully and decided to use it. However, if any of any of the following applies to you, tell your doctor immediately. _WHEN YOU MUST NOT USE IT _ YOU SHOULD NOT BE GIVEN NEOSTIGMINE Aqra d-dokument sħiħ
Neostigmine Juno PI Page | 1 AUSTRALIAN PRODUCT INFORMATION NEOSTIGMINE JUNO (_NEOSTIGMINE METHYLSULFATE) _ _INJECTION_ _ _ 1 NAME OF THE MEDICINE Neostigmine methylsulfate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Neostigmine Juno injection contains 2.5 mg neostigmine methylsulfate in 1 mL solution. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS. 3. PHARMACEUTICAL FORM Neostigmine Juno Solution for Injection is a clear, colourless sterile solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Neostigmine is indicated for: Reversal of the effects of non-depolarising neuromuscular blocking agents. Prophylaxis and treatment of post-operative intestinal atony and urinary retention. Treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates. 4.2 DOSE AND METHOD OF ADMINISTRATION Neostigmine Juno Solution for Injection can be given as an intramuscular (IM), intravenous (IV) or subcutaneous (SC) injection. The following doses are approximately equivalent in effect: 0.5 mg IV = 1.0 - 1.5 mg IM or SC. When Neostigmine Juno Solution for Injection is given, a syringe of atropine sulfate or glycopyrrolate should be available to counteract severe cholinergic reactions, if they occur. Do not mix atropine with other drugs in the same syringe as compatibility data are not available. Neostigmine Juno Solution for Injection in ampoules contains no antimicrobial agent. It should be used once and any residue discarded. ANTAGONIST TO NONDEPOLARISING NEUROMUSCULAR BLOCKADE: Usually, reversal of neuromuscular blockade with Neostigmine Juno Solution for Injection should not be attempted until spontaneous recovery from paralysis is evident. It is recommended that the patient be well ventilated and patent airway maintained until complete recovery of normal respiration is affirmed. Neostigmine should be administered when the first twitch response is substantially greater Neostigmine Juno PI Page | 2 than 10% of baseline, or when a second twitch is present. Aqra d-dokument sħiħ